A 1-month-old infant with chylomicronemia due to GPIHBP1 gene mutation treated by plasmapheresis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chylomicronemia is a severe type of hypertriglyceridemia characterized by chylomicron accumulation that arises from a genetic defect in intravascular lipolysis. It requires urgent and proper management, because serious cases can be accompanied by pancreatic necrosis or persistent multiple organ failure. We present the case of a 1-month-old infant with chylomicronemia treated by plasmapheresis. His chylomicronemia was discovered incidentally when lactescent plasma was noticed during routine blood sampling during a hospital admission for fever and irritability. Laboratory investigation revealed marked triglyceridemia (>5,000 mg/dL) with high chylomicron levels. We therefore decided to perform a therapeutic plasmapheresis to prevent acute pancreatitis. Sequence analysis revealed a homozygous novel mutation in exon 4 of GPIHBP1: c.476delG (p.Gly159Alafs). Glycosylphosphatidylinositol-anchored high density lipoproteinbinding protein 1 (GPIHBP1) stabilizes the binding of chylomicrons near lipoprotein lipase and supports lipolysis. Mutations of GPIHBP1, the most recently discovered gene, can lead to severe hyperlipidemia and are known to make up only 2% of the monogenic mutations associated with chylomicronemia. The patient maintains mild hypertriglyceridemia without rebound after single plasmapheresis and maintenance fibrate medication so far. Here, we report an infant with chylomicronemia due to GPIHBP1 mutation, successfully treated by plasmapheresis.
Abstract
Chylomicronemia is a severe type of hypertriglyceridemia characterized by chylomicron accumulation that arises from a genetic defect in intravascular lipolysis. It requires urgent and proper management, because serious cases can be accompanied by pancreatic necrosis or persistent multiple organ failure. We present the case of a 1-month-old infant with chylomicronemia treated by plasmapheresis. His chylomicronemia was discovered incidentally when lactescent plasma was noticed during routine blood sampling during a hospital admission for fever and irritability. Laboratory investigation revealed marked triglyceridemia (>5,000 mg/dL) with high chylomicron levels. We therefore decided to perform a therapeutic plasmapheresis to prevent acute pancreatitis. Sequence analysis revealed a homozygous novel mutation in exon 4 of GPIHBP1: c.476delG (p.Gly159Alafs). Glycosylphosphatidylinositol-anchored high density lipoproteinbinding protein 1 (GPIHBP1) stabilizes the binding of chylomicrons near lipoprotein lipase and supports lipolysis. Mutations of GPIHBP1, the most recently discovered gene, can lead to severe hyperlipidemia and are known to make up only 2% of the monogenic mutations associated with chylomicronemia. The patient maintains mild hypertriglyceridemia without rebound after single plasmapheresis and maintenance fibrate medication so far. Here, we report an infant with chylomicronemia due to GPIHBP1 mutation, successfully treated by plasmapheresis.
참고문헌 (20)
- Hegele RA, "The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management", Lancet Diabetes Endocrinol, 2, pp.655~666 (2014)
- Brahm AJ, "Chylomicronaemia: current diagnosis and future therapies", Nat Rev Endocrinol, 11, pp.352~362 (2015)
- Santamarina-Fojo S, "The familial chylomicronemia syndrome", Endocrinol Metab Clin North Am, 27, pp.551~567 (1998)
- Valdivielso P, "Current knowledge of hypertriglyceridemic pancreatitis", Eur J Intern Med, 25, pp.689~694 (2014)
- Young SG, "Biochemistry and pathophysiology of intravascular and intracellular lipolysis", Genes Dev, 27, pp.459~484 (2013)
- Johansen CT, "Genetic determinants of plasma triglycerides", J Lipid Res, 52, pp.189~206 (2011)
- Adeyo O, "Glycosylphosphatidylinositolanchored high-density lipoprotein-binding protein 1 and the intravascular processing of triglyceride-rich lipoproteins", J Intern Med, 272, pp.528~540 (2012)
- Rios JJ, "Deletion of GPIHBP1 causing severe chylomicronemia", J Inherit Metab Dis, 35, pp.531~540 (2012)
- Davies BS, "GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries", Cell Metab, 12, pp.42~52 (2010)
- Beigneux AP, "Glycosylphosphatidylinositol-anchored highdensity lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons", Cell Metab, 5, pp.279~291 (2007)
- Patni N, "Type 1 hyperlipoproteinemia in a child with large homozygous deletion encompassing GPIHBP1", J Clin Lipidol, 10, pp.265~270 (2016)
- Gotoda T, "Diagnosis and management of type I and type V hyperlipoproteinemia", J Atheroscler Thromb, 19, pp.1~12 (2012)
- Yuan G, "Hypertriglyceridemia: its etiology, effects and treatment", CMAJ, 176, pp.1113~1120 (2007)
- Basel-Vanagaite L, "Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1", Am J Hum Genet, 90, pp.49~60 (2012)
- Ahmad Z, "Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1", J Clin Lipidol, 8, pp.635~639 (2014)
- Becker M, "Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate", Pediatrics, 89, pp.138~142 (1992)
- Szczepiorkowski ZM, "Guidelines on the use of therapeutic apheresis in clinical practice-- evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis", J Clin Apher, 25, pp.83~177 (2010)
- Stefanutti C, "Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks", Transfus Apher Sci, 31, pp.3~10 (2004)
- Stefanutti C, "A three month-old infant with severe hyperchylomicronemia: molecular diagnosis and extracorporeal treatment", Atheroscler Suppl, 14, pp.73~76 (2013)
- Sacks FM, "Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide", JAMA Intern Med, 174, pp.443~447 (2014)